Advertisements



Provention Bio expects results of inflammatory bowel disease trials in 2H19

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 11th, 2018

Provention Bio sees results of inflammatory bowel disease trials in 2H19

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 11th, 2018

Quotient Limited Recaps Recent Milestone Achievement and Updates on the Initial Serological Disease Screening CE Mark Submission, planned 2019 US Field Trials and Reports Record Financial Results

CE mark received on the initial Immunohematology microarray in April 2019 2018 manufacturing site certification and MosaiQ™ device CE mark combine with the recent approval to permit commercialization Successful European field .....»»

Category: earningsSource: benzingaMay 28th, 2019

InflaRx Full Year 2018 Financial & Operating Results

$62.9 million (€53.0 million) raised in a follow-on offering to advance clinical programs for IFX-1 Start of three Phase II trials for IFX-1 in two serious inflammatory diseases Expansion of our operations along a number of fronts.....»»

Category: earningsSource: benzingaMar 28th, 2019

Good Bacteria Could Be Used to Fight Gut Diseases, New Research Suggests

The findings could lead to a treatment for inflammatory bowel disease......»»

Category: topSource: newsweekJul 4th, 2018

Akari Announces First Quarter 2018 Financial Results and Update on its Growing Pipeline of Phase II and Phase III Clinical Trials

Opened three clinical trials in 2018 Trials in which complement dysregulation is the primary disease driver CAPSTONE, the Phase III trial in naïve paroxysmal nocturnal hemoglobinuria (PNH), in which patient treatment has commenced Phase II U.S. trial f.....»»

Category: earningsSource: benzingaAug 17th, 2018

Novan Rallies On Positive Early Results For Inflammatory Skin Disease Medication

Novan Inc (NASDAQ: NOVN) shares were advancing strongly Monday after the announcement of positive results for its pipeline candidate SB414. read more.....»»

Category: blogSource: benzingaAug 20th, 2018

UPMC Health Plan announces $6.3M research contract

UPMC Health Plan announced that the UPMC Center for High-Value Health Care was recently awarded a $6.3 million contract from the Patient-Centered Outcomes Research Institute (PCORI) to improve outcomes for patients with inflammatory bowel disease (.....»»

Category: topSource: bizjournalsSep 25th, 2018

Protagonist Therapeutics begins Phase 1 trial of inflammatory bowel disease drug

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 13th, 2018

Fired Amazon worker with Crohn"s sues over bathroom breaks

A former Amazon employee in Kentucky with the inflammatory bowel condition known as Crohn's disease has sued the company over his dismissal for what he says was a need for more bathroom breaks......»»

Category: topSource: foxnewsFeb 22nd, 2019

Transceiver module maker PCL positive about outlook for 2H19

Optical transceiver module maker TCL Technologies expects its shipments of 32G transceiver modules to grow 5-10% month-by-month starting July despite the uncertainty arising from the US-China trade dispute, according to company chairman Gene Chen......»»

Category: topSource: digitimesJun 10th, 2019

Provention Bio announces results from At Risk study in Type 1 Diabetes

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 9th, 2019

Kraft Heinz completes internal investigation on procurement practices

Kraft Heinz Co said on Friday the company's internal investigation into its procurement practices and internal controls assessment is now complete and expects to report its quarterly results on or before July 31......»»

Category: topSource: reutersJun 7th, 2019

Beyond Meat sees sales doubling in 2019, shares rise 16%

Plant-based burger maker Beyond Meat Inc on Thursday reported quarterly revenue above analysts' estimates in its first results since going public, and said it expects to double its sales this year......»»

Category: topSource: reutersJun 6th, 2019

Report: UBS expects public concerns over Boeing 737 MAX to fade

If the Boeing Co. executes a safe return to service of its 737 MAX, analysts at UBS say new survey results indicate that most future passengers will feel safe flying on the aircraft.   According to a report from MarketWatch, a new UBS survey of mor.....»»

Category: topSource: bizjournalsJun 4th, 2019

Spectrum announces integrated results from to Phase 3 ROLONTIS trials

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 2nd, 2019

Mexican president expects good results from U.S. talks on tariffs

Mexican President Andres M.....»»

Category: topSource: reutersJun 1st, 2019

Universal mCloud Reports First Quarter 2019 Results

Q1 2019 revenues grew to C$2.2 million, up over 500% compared to Q1 2018  Expects to sign definitive agreements .....»»

Category: earningsSource: benzingaMay 30th, 2019

The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo"s Brittle Bone Disease Drug

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 29) read more.....»»

Category: blogSource: benzingaMay 30th, 2019

Akari Therapeutics Reports First Quarter 2019 Financial Results And Highlights Recent Clinical Progress

Positive initial clinical data reported in ongoing bullous pemphigoid (BP) and atopic keratoconjunctivitis (AKC) clinical trials Further clinical data from BP and AKC trials anticipa.....»»

Category: earningsSource: benzingaMay 29th, 2019

Sol-Gel Technologies Reports First Quarter 2019 Financial Results and Corporate Update

Top-line results from Phase III Epsolay® and TWIN trials remain on track; mid-2019 and 4Q19, respectfully Reports top-line generic product revenues of $6.3 million NESS ZIONA, Israel, May 22.....»»

Category: earningsSource: benzingaMay 22nd, 2019